MedPath

Medication Reconciliation in Pulmonary Hypertension

Completed
Conditions
Pulmonary Arterial Hypertension
Pulmonary Hypertension Chronic Thromboembolic
Pulmonary Hypertension
Interventions
Other: Medication reconciliation
Registration Number
NCT04744584
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Brief Summary

Pulmonary hypertension (PH) is a life threatening condition. In PH, pulmonary arterial hypertension (PAH) and chronic thrombo-embolic chronic pulmonary hypertension (CTEPH) are two rare diseases requiring specific and complex drug management. In France ,a part of these treatments ,only available in hospital pharmacies, are generally unknown from community health care professionals despite the high risk of drug-interactions and side effects. Anticipating medication errors at the begging of the disease is therefore important, and could be done through medication reconciliation.

Detailed Description

Medication reconciliation (MR) will be done for patients hospitalized in the French referral center for PH for PAH or CTEPH. Detected medication errors will be tracked and fixed by the physician before the end of hospitalization. A synthesis of new/stopped and modified treatments will be given to the patient as well as his related healthcare professionals (community pharmacist and general practioner) to ensure the maintaining of the new therapeutic management and the understanding of drugs modification. To compare the potential decrease of medication errors promoted by MR, a retrospective MR will be also done for patients without MR at 1st hospitalization but at the next one (3 to 12 months after).

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
129
Inclusion Criteria
  • Patient affiliated or entitled to a social security scheme
  • At least 18 years old
  • Patient with enlightened information of the study and not opposed with it.
  • For patient without MR: patient hospitalized for the first re-evaluation of PAH or CTEPH within 12 months following the first assessment hospitalization (ie: first right heart catheterization at bicetre Hospital).
  • For patient with MR: patient hospitalized for first assessment (first right heart catheterization at bicetre Hospital) of PAH or CTEPH
Exclusion Criteria
  • Patient suffering from another form of PH
  • Patient under guardianship or curator
  • Inability to give information to the patient either due to language barrier or to cognitive impairment
  • Patient hosted in institution on discharge from hospital (follow-up care and long-term rehabilitation)
  • Patient with a life expectancy of less than 1 year
  • Patient on transplant list
  • Patient refusal
  • Length of stay < 48 hours

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Patients without medication reconciliationMedication reconciliationPatient without medication reconciliation (MR) at 1st hospitalization but with retrospective MR at the next one (3 to 6 months after)
Patients with medication reconciliationMedication reconciliationPatient with medication reconciliation during 1st hospitalization
Primary Outcome Measures
NameTimeMethod
Proportion of patients having at least one medication error on discharge at the first hospitalization.12months

This group will be compared to patients without prospective MR. For the latter group, MR is retrospective (3 to 6 months after discharge).

Secondary Outcome Measures
NameTimeMethod
Emergency hospitalizationwithin 12 months after first hospitalization for the diagnosis of the disease

Number of emergency hospitalizations between first assessment hospitalization (diagnosis) and first reassessment hospitalization

Estimate the time and resources spent on the conciliation process in the department12 months

Time measurement of the conciliation process in the group with CM (in minutes)

Identification of medication error severity12 months

Cornish scale is the title of the scale which include 3 levels of gravity (from 1 to 3). The first one describes no relevant clinical impact and the third one describes a severe clinical impact.

Qualitative description of identified medication errors.12 months

Omission, dosing errors, drug interactions, substitution of another active compound

Medication errors status12 Months

corrected/not corrected

Therapeutic adherencewithin 12 months after first hospitalization for the diagnosis of the disease

Observance Girerd auto-questionnaire

Satisfaction of community healthcare practitioners with study tools12 months

healthcare practitioners will be contacted by mail or phone

Improve vaccination coverage against influenza and pneumococcal diseasewithin 12 months after first hospitalization for the diagnosis of the disease

inclusion vaccination coverage rate vs EOS(Enhanced Outreach Strategy) vaccination coverage rate

Measure of Quality of lifewithin 12 months after first hospitalization for the diagnosis of the disease

Short Form 36 Questionnaire

Trial Locations

Locations (1)

Hospital BICETRE

🇫🇷

Le Kremlin-Bicêtre, France

© Copyright 2025. All Rights Reserved by MedPath